Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.

Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH.

Pediatr Res. 2012 Jul;72(1):43-9. doi: 10.1038/pr.2012.51. Epub 2012 Apr 11.

PMID:
22495532
2.

The treatment of neonatal seizures: focus on Levetiracetam.

Loiacono G, Masci M, Zaccara G, Verrotti A.

J Matern Fetal Neonatal Med. 2016;29(1):69-74. doi: 10.3109/14767058.2014.986651. Epub 2014 Dec 5. Review.

PMID:
25385270
3.

Levetiracetam: safety and efficacy in neonatal seizures.

Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J.

Eur J Paediatr Neurol. 2011 Jan;15(1):1-7. doi: 10.1016/j.ejpn.2010.10.003. Epub 2010 Nov 19.

PMID:
21094062
4.

Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.

Patterson EE, Goel V, Cloyd JC, O'Brien TD, Fisher JE, Dunn AW, Leppik IE.

J Vet Pharmacol Ther. 2008 Jun;31(3):253-8. doi: 10.1111/j.1365-2885.2008.00948.x.

PMID:
18471147
5.

Role of intravenous levetiracetam for acute seizure management in preterm neonates.

Khan O, Cipriani C, Wright C, Crisp E, Kirmani B.

Pediatr Neurol. 2013 Nov;49(5):340-3. doi: 10.1016/j.pediatrneurol.2013.05.008. Epub 2013 Aug 3.

PMID:
23921284
6.

Use of Levetiracetam in Neonates in Clinical Practice: A Retrospective Study at a German University Hospital.

Neininger MP, Ullmann M, Dahse AJ, Syrbe S, Bernhard MK, Frontini R, Kiess W, Merkenschlager A, Thome U, Bertsche T, Bertsche A.

Neuropediatrics. 2015 Oct;46(5):329-34. doi: 10.1055/s-0035-1558969. Epub 2015 Aug 26.

PMID:
26308219
7.

Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy.

Muñana KR, Nettifee-Osborne JA, Papich MG.

J Vet Intern Med. 2015 Mar-Apr;29(2):614-9. doi: 10.1111/jvim.12548. Epub 2015 Feb 25.

8.

Pharmacokinetics of levetiracetam in neonates with seizures.

Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, Vinks AA.

J Pediatr. 2011 Jul;159(1):152-154.e3. doi: 10.1016/j.jpeds.2011.03.057. Epub 2011 May 18.

9.

Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures.

Shin JW, Jung YS, Park K, Lee SM, Eun HS, Park MS, Park KI, Namgung R.

Korean J Pediatr. 2017 Feb;60(2):50-54. doi: 10.3345/kjp.2017.60.2.50. Epub 2017 Feb 27.

10.

Efficacy and safety of levetiracetam in the management of seizures in neonates.

Sedighi M, Asadi F, Moradian N, Vakiliamini M, Moradian M.

Neurosciences (Riyadh). 2016 Jul;21(3):232-5. doi: 10.17712/nsj.2016.3.20150726.

11.

Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.

Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A.

Epilepsia. 2006 Jul;47(7):1128-35.

12.

Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.

Moore SA, Muñana KR, Papich MG, Nettifee-Osborne J.

Am J Vet Res. 2010 Mar;71(3):337-41. doi: 10.2460/ajvr.71.3.337.

PMID:
20187836
13.

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.

Hardy BT, Patterson EE, Cloyd JM, Hardy RM, Leppik IE.

J Vet Intern Med. 2012 Mar-Apr;26(2):334-40. doi: 10.1111/j.1939-1676.2011.00868.x. Epub 2012 Feb 1.

14.

Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures.

Maitre NL, Smolinsky C, Slaughter JC, Stark AR.

J Perinatol. 2013 Nov;33(11):841-6. doi: 10.1038/jp.2013.116. Epub 2013 Sep 19.

15.

Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.

Tomson T, Palm R, Källén K, Ben-Menachem E, Söderfeldt B, Danielsson B, Johansson R, Luef G, Ohman I.

Epilepsia. 2007 Jun;48(6):1111-6. Epub 2007 Mar 22.

16.

Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).

Yan HD, Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M.

Epilepsia. 2005 Aug;46(8):1170-7.

17.

Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.

Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M.

Epilepsia. 2001 Jul;42(7):825-30.

18.

Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.

Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB.

Pharmacotherapy. 2011 Oct;31(10):934-41. doi: 10.1592/phco.31.10.934.

PMID:
21950640
19.

Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.

Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G.

Epilepsia. 2009 May;50(5):1150-7. doi: 10.1111/j.1528-1167.2008.01974.x. Epub 2009 Jan 19.

20.

Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.

Abend NS, Monk HM, Licht DJ, Dlugos DJ.

Pediatr Crit Care Med. 2009 Jul;10(4):505-10. doi: 10.1097/PCC.0b013e3181a0e1cf.

Supplemental Content

Support Center